Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Enhanced human hematopoietic stem and progenitor cell engraftment by blocking donor T cell-mediated TNFα signaling.

Wang W, Fujii H, Kim HJ, Hermans K, Usenko T, Xie S, Luo ZJ, Ma J, Celso CL, Dick JE, Schroeder T, Krueger J, Wall D, Egeler RM, Zandstra PW.

Sci Transl Med. 2017 Dec 20;9(421). pii: eaag3214. doi: 10.1126/scitranslmed.aag3214.

PMID:
29263228
2.

Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, Ishii E, Janka G, Ladisch S, Lehmberg K, McClain KL, Minkov M, Montgomery S, Nanduri V, Rosso D, Henter JI.

Blood. 2017 Dec 21;130(25):2728-2738. doi: 10.1182/blood-2017-06-788349. Epub 2017 Sep 21.

3.

Tertiary lymphoid structures are confined to patients presenting with unifocal Langerhans Cell Histiocytosis.

Quispel WT, Steenwijk EC, van Unen V, Santos SJ, Koens L, Mebius R, Egeler RM, van Halteren AG.

Oncoimmunology. 2016 Mar 28;5(8):e1164364. doi: 10.1080/2162402X.2016.1164364. eCollection 2016 Aug.

4.

Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series.

Chellapandian D, Makras P, Kaltsas G, van den Bos C, Naccache L, Rampal R, Carret AS, Weitzman S, Egeler RM, Abla O.

Mediterr J Hematol Infect Dis. 2016 Jul 1;8(1):e2016033. doi: 10.4084/MJHID.2016.033. eCollection 2016.

5.

Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.

Egeler RM, Katewa S, Leenen PJ, Beverley P, Collin M, Ginhoux F, Arceci RJ, Rollins BJ; Steering Committee of the Nikolas Symposium.

Pediatr Blood Cancer. 2016 Oct;63(10):1704-12. doi: 10.1002/pbc.26104. Epub 2016 Jun 17. Review.

PMID:
27314817
6.

Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms.

Wiekmeijer AS, Pike-Overzet K, Brugman MH, van Eggermond MCJA, Cordes M, de Haas EFE, Li Y, Oole E, van IJcken WFJ, Egeler RM, Meijerink JP, Staal FJT.

Exp Hematol. 2016 Sep;44(9):838-849.e9. doi: 10.1016/j.exphem.2016.06.002. Epub 2016 Jun 11.

PMID:
27302866
7.

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.

Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J.

J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6.

PMID:
27269950
8.

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM; Histiocyte Society.

Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10. Review.

9.

Erratum to: Intact IFN-γR1 Expression and Function Distinguishes Langerhans Cell Histiocytosis From Mendelian Susceptibility to Mycobacterial Disease.

Quispel WT, Stegehuis-Kamp JA, Santos SJ, van Wengen A, Dompeling E, Egeler RM, van de Vosse E, van Halteren AG.

J Clin Immunol. 2016 Feb;36(2):171-2. doi: 10.1007/s10875-016-0235-z. No abstract available.

PMID:
26783113
10.

Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients.

Nierkens S, Lankester AC, Egeler RM, Bader P, Locatelli F, Pulsipher MA, Bollard CM, Boelens JJ; Westhafen Intercontinental Group.

Cytotherapy. 2015 Dec;17(12):1667-74. doi: 10.1016/j.jcyt.2015.09.008. Review.

PMID:
26589751
11.

Activated Conventional T-Cells Are Present in Langerhans Cell Histiocytosis Lesions Despite the Presence of Immune Suppressive Cytokines.

Quispel WT, Stegehuis-Kamp JA, Santos SJ, Egeler RM, van Halteren AG.

J Interferon Cytokine Res. 2015 Oct;35(10):831-9. doi: 10.1089/jir.2014.0190. Epub 2015 Sep 18.

PMID:
26381039
12.

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.

Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2154-2159. doi: 10.1016/j.bbmt.2015.08.023. Epub 2015 Aug 29.

13.

The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome.

Quispel WT, Stegehuis-Kamp JA, Blijleven L, Santos SJ, Lourda M, van den Bos C, van Halteren AG, Egeler RM.

Oncoimmunology. 2015 Aug 31;5(3):e1084463. doi: 10.1080/2162402X.2015.1084463. eCollection 2016 Mar.

14.

Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.

Calkoen FG, Vervat C, Eising E, Vijfhuizen LS, 't Hoen PB, van den Heuvel-Eibrink MM, Egeler RM, van Tol MJ, Ball LM.

Haematologica. 2015 Nov;100(11):1434-41. doi: 10.3324/haematol.2015.126938. Epub 2015 Aug 20.

15.

Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.

Fujii H, Luo ZJ, Kim HJ, Newbigging S, Gassas A, Keating A, Egeler RM.

PLoS One. 2015 Jul 15;10(7):e0133216. doi: 10.1371/journal.pone.0133216. eCollection 2015.

16.

Reactivation of Human Herpes Virus-6 After Pediatric Stem Cell Transplantation: Risk Factors, Onset, Clinical Symptoms and Association With Severity of Acute Graft-Versus-Host Disease.

Verhoeven DH, Claas EC, Jol-van der Zijde CM, Thijssen JC, Lankester AC, Bredius RG, Putter H, Kroes AC, Egeler RM, Schilham MW, van Tol MJ.

Pediatr Infect Dis J. 2015 Oct;34(10):1118-27. doi: 10.1097/INF.0000000000000824.

PMID:
26132825
17.

Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.

Hutspardol S, Essa M, Richardson S, Schechter T, Ali M, Krueger J, Fujii H, Egeler RM, Gassas A.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1802-7. doi: 10.1016/j.bbmt.2015.06.015. Epub 2015 Jun 25.

18.

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.

Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, Grunebaum E, Dupuis LL.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1471-8. doi: 10.1016/j.bbmt.2015.05.006. Epub 2015 May 11.

19.

Serum Krebs Von Den Lungen-6 as a Biomarker for Early Detection of Bronchiolitis Obliterans Syndrome in Children Undergoing Allogeneic Stem Cell Transplantation.

Gassas A, Schechter T, Krueger J, Craig-Barnes H, Sung L, Ali M, Dell S, Egeler RM, Zaidman I, Palaniyar N.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1524-8. doi: 10.1016/j.bbmt.2015.04.021. Epub 2015 May 8.

20.

MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.

Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ.

Genes Chromosomes Cancer. 2015 Jun;54(6):361-8. doi: 10.1002/gcc.22247. Epub 2015 Mar 31.

PMID:
25899310
21.

Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.

Boerman GH, van Ostaijen-ten Dam MM, Kraal KC, Santos SJ, Ball LM, Lankester AC, Schilham MW, Egeler RM, van Tol MJ.

Cancer Immunol Immunother. 2015 May;64(5):573-83. doi: 10.1007/s00262-015-1657-9. Epub 2015 Feb 18.

22.

Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning.

Veys PA, Nanduri V, Baker KS, He W, Bandini G, Biondi A, Dalissier A, Davis JH, Eames GM, Egeler RM, Filipovich AH, Fischer A, Jürgens H, Krance R, Lanino E, Leung WH, Matthes S, Michel G, Orchard PJ, Pieczonka A, Ringdén O, Schlegel PG, Sirvent A, Vettenranta K, Eapen M.

Br J Haematol. 2015 Jun;169(5):711-8. doi: 10.1111/bjh.13347. Epub 2015 Mar 27.

23.

Expression of the immune regulation antigen CD70 in osteosarcoma.

Pahl JH, Santos SJ, Kuijjer ML, Boerman GH, Sand LG, Szuhai K, Cleton-Jansen A, Egeler RM, Boveé JV, Schilham MW, Lankester AC.

Cancer Cell Int. 2015 Mar 18;15:31. doi: 10.1186/s12935-015-0181-5. eCollection 2015.

24.

Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro.

Calkoen FG, Vervat C, van Pel M, de Haas V, Vijfhuizen LS, Eising E, Kroes WG, 't Hoen PA, van den Heuvel-Eibrink MM, Egeler RM, van Tol MJ, Ball LM.

Stem Cell Res. 2015 Mar;14(2):198-210. doi: 10.1016/j.scr.2015.01.006. Epub 2015 Jan 28.

25.

Histologic patterns of thymic involvement in Langerhans cell proliferations: a clinicopathologic study and review of the literature.

Picarsic J, Egeler RM, Chikwava K, Patterson K, Jaffe R.

Pediatr Dev Pathol. 2015 Mar-Apr;18(2):127-38. doi: 10.2350/15-01-1593-OA.1. Epub 2015 Jan 28. Review.

PMID:
25629953
26.

Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion.

Patrick K, Lau W, Gassas A, McDougall E, Doyle J, Ali M, Krueger J, Courtney S, Armstrong C, Egeler RM, Schechter T.

Bone Marrow Transplant. 2015 Apr;50(4):536-9. doi: 10.1038/bmt.2014.309. Epub 2015 Jan 26.

PMID:
25621802
27.

Sustained Engraftment of Cryopreserved Human Bone Marrow CD34(+) Cells in Young Adult NSG Mice.

Wiekmeijer AS, Pike-Overzet K, Brugman MH, Salvatori DC, Egeler RM, Bredius RG, Fibbe WE, Staal FJ.

Biores Open Access. 2014 Jun 1;3(3):110-6. doi: 10.1089/biores.2014.0008.

28.

Mesenchymal stromal cell therapy is associated with increased adenovirus-associated but not cytomegalovirus-associated mortality in children with severe acute graft-versus-host disease.

Calkoen FG, Vervat C, van Halteren AG, Welters MJ, Veltrop-Duits LA, Lankester AC, Egeler RM, Ball LM, van Tol MJ.

Stem Cells Transl Med. 2014 Aug;3(8):899-910. doi: 10.5966/sctm.2013-0191. Epub 2014 Jun 5.

29.

Exercise intolerance and the impact of physical activity in children treated with hematopoietic stem cell transplantation.

West SL, Gassas A, Schechter T, Egeler RM, Nathan PC, Wells GD.

Pediatr Exerc Sci. 2014 Aug;26(3):358-64. doi: 10.1123/pes.2013-0156. Epub 2014 Apr 10. Review.

PMID:
24721685
30.

Somatic activating ARAF mutations in Langerhans cell histiocytosis.

Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovée JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ.

Blood. 2014 May 15;123(20):3152-5. doi: 10.1182/blood-2013-06-511139. Epub 2014 Mar 20.

PMID:
24652991
31.

Patient reported outcomes in pediatric oncology practice: suggestions for future usage by parents and pediatric oncologists.

Schepers SA, Engelen VE, Haverman L, Caron HN, Hoogerbrugge PM, Kaspers GJ, Egeler RM, Grootenhuis MA.

Pediatr Blood Cancer. 2014 Sep;61(9):1707-10. doi: 10.1002/pbc.25034. Epub 2014 Mar 20.

PMID:
24648289
32.

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.

Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, Jiskoot W, Lankester AC, Schilham MW.

J Exp Clin Cancer Res. 2014 Mar 10;33:27. doi: 10.1186/1756-9966-33-27.

33.

Intact IFN-γR1 expression and function distinguishes Langerhans cell histiocytosis from mendelian susceptibility to mycobacterial disease.

Quispel WT, Stegehuis-Kamp JA, Santos SJ, van Wengen A, Dompeling E, Egeler RM, van de Vosse E, van Halteren AG.

J Clin Immunol. 2014 Jan;34(1):84-93. doi: 10.1007/s10875-013-9959-1. Epub 2013 Nov 20. Review. Erratum in: J Clin Immunol. 2014 Jul;34(5):600. J Clin Immunol. 2016 Feb;36(2):171-2.

PMID:
24254535
34.

Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.

Calkoen FG, Jol-van der Zijde CM, Mearin ML, Schweizer JJ, Jansen-Hoogendijk AM, Roelofs H, van Halteren AG, Egeler RM, van Tol MJ, Ball LM.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1590-9. doi: 10.1016/j.bbmt.2013.08.006. Epub 2013 Aug 28.

35.

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.

Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F.

Br J Haematol. 2013 Nov;163(4):501-9. doi: 10.1111/bjh.12545. Epub 2013 Aug 31.

PMID:
23992039
36.

Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.

Schultz RK, Baker KS, Boelens JJ, Bollard CM, Egeler RM, Cowan M, Ladenstein R, Lankester A, Locatelli F, Lawitschka A, Levine JE, Loh M, Nemecek E, Niemeyer C, Prasad VK, Rocha V, Shenoy S, Strahm B, Veys P, Wall D, Bader P, Grupp SA, Pulsipher MA, Peters C.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1279-87. doi: 10.1016/j.bbmt.2013.07.006. Epub 2013 Jul 21.

37.

Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.

Dupuis LL, Seto W, Teuffel O, Gibson P, Schultz KR, Doyle JD, Gassas A, Egeler RM, Sung L, Schechter T.

Biol Blood Marrow Transplant. 2013 Mar;19(3):418-23. doi: 10.1016/j.bbmt.2012.10.031. Epub 2012 Nov 2.

38.

Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.

Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J; Euro Histio Network.

Pediatr Blood Cancer. 2013 Feb;60(2):175-84. doi: 10.1002/pbc.24367. Epub 2012 Oct 25.

39.

Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity.

Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Egeler RM, Arceci RJ.

Br J Haematol. 2012 Nov;159(3):299-310. doi: 10.1111/bjh.12033. Epub 2012 Aug 30.

PMID:
22934889
40.

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.

Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh' EP, Egeler RM, Hogendoorn PC, Lankester AC.

Clin Sarcoma Res. 2012 Feb 8;2(1):8. doi: 10.1186/2045-3329-2-8.

41.

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients.

Buddingh EP, Ruslan SE, Berghuis D, Gelderblom H, Anninga JK, Hogendoorn PC, Egeler RM, Schilham MW, Lankester AC.

Cancer Immunol Immunother. 2012 Jun;61(6):941-7. doi: 10.1007/s00262-012-1232-6. Epub 2012 Mar 10.

42.

Managing a dual role--experiences and coping strategies of parents donating haploidentical G-CSF mobilized peripheral blood stem cells to their children.

van Walraven SM, Ball LM, Koopman HM, Switzer GE, Ropes-de Jong CM, de Jong A, Bredius RG, Egeler RM.

Psychooncology. 2012 Feb;21(2):168-75. doi: 10.1002/pon.1885. Epub 2010 Dec 19.

PMID:
22271537
43.

Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.

Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PC, Egeler RM, Schilham MW, Lankester AC.

Clin Cancer Res. 2012 Jan 15;18(2):432-41. doi: 10.1158/1078-0432.CCR-11-2277. Epub 2011 Nov 16.

44.

In situ detection of HY-specific T cells in acute graft-versus-host disease-affected male skin after sex-mismatched stem cell transplantation.

Kim YH, Faaij CM, van Halteren AG, Schrama E, de Jong TA, Schøller J, Egeler RM, Pavel S, Vyth-Dreese FA, van Tol MJ, Goulmy E, Spierings E.

Biol Blood Marrow Transplant. 2012 Mar;18(3):381-7. doi: 10.1016/j.bbmt.2011.10.038. Epub 2011 Nov 4.

45.

Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.

te Winkel ML, Pieters R, Hop WC, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, Bökkerink JP, Leeuw JA, Bruin MC, Egeler RM, Veerman AJ, van den Heuvel-Eibrink MM.

J Clin Oncol. 2011 Nov 1;29(31):4143-50. doi: 10.1200/JCO.2011.37.3217. Epub 2011 Sep 26.

PMID:
21947829
46.

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.

Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, Henter JI; Histiocyte Society.

Blood. 2011 Oct 27;118(17):4577-84. doi: 10.1182/blood-2011-06-356261. Epub 2011 Sep 6.

47.

IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD.

Jol-van der Zijde CM, Bredius RG, Jansen-Hoogendijk AM, Raaijmakers S, Egeler RM, Lankester AC, van Tol MJ.

Bone Marrow Transplant. 2012 Mar;47(3):360-8. doi: 10.1038/bmt.2011.166. Epub 2011 Sep 5.

PMID:
21892212
48.

Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group.

Jöris MM, Bierings MB, Egeler RM, Claas FH, van Rood JJ, Oudshoorn M.

Bone Marrow Transplant. 2012 May;47(5):677-83. doi: 10.1038/bmt.2011.168. Epub 2011 Aug 22.

PMID:
21860428
49.

Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?

Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM.

Eur J Cancer. 2011 Nov;47(16):2431-45. doi: 10.1016/j.ejca.2011.05.030. Epub 2011 Jun 22. Review.

PMID:
21703851
50.

Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: is it effective?

Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, Egeler RM, Kaspers G, Grootenhuis M.

Pediatr Blood Cancer. 2012 May;58(5):766-74. doi: 10.1002/pbc.23158. Epub 2011 May 16.

PMID:
21584933

Supplemental Content

Loading ...
Support Center